PURPOSE: Congenital hyperinsulinism of infancy (OMIM# 256450) is a devastating disease most commonly caused by dominant or recessive mutations in either ABCC8 or KCNJ11, the genes that encode for the β-cell adenosine triphosphate-regulated potassium channel. A unique combination of a paternally inherited germline mutation and somatic loss-of-heterozygosity causes the focal form of the disease (Focal-congenital hyperinsulinism of infancy [Focal-CHI]), the incidence of which in genetically susceptible individuals is not known. METHODS: We genotyped 21,122 Ashkenazi Jewish individuals for two previously identified ABCC8 founder mutations and utilized a clinical database of 61 unrelated Ashkenazi patients with congenital hyperinsulinism of infancy to obtain an estimate of the risk of Focal-CHI in a genetically susceptible fetus. RESULTS: The combined mutation carrier rate in Ashkenazi Jews was 1:52, giving an estimated frequency of homozygosity or compound heterozygosity of 1:10,816 in this population. The risk of Focal-CHI is 1:540 per pregnancy in offspring of carrier fathers. CONCLUSION: We recommend that these mutations be included in the genetic screening program for the Ashkenazi Jewish population. As the risk of Focal-CHI is not expected to be mutation specific, the data reported in this study are useful for counseling all families in which the father was found to carry a recessive ABCC8 or KCNJ11 mutation.
PURPOSE: Congenital hyperinsulinism of infancy (OMIM# 256450) is a devastating disease most commonly caused by dominant or recessive mutations in either ABCC8 or KCNJ11, the genes that encode for the β-cell adenosine triphosphate-regulated potassium channel. A unique combination of a paternally inherited germline mutation and somatic loss-of-heterozygosity causes the focal form of the disease (Focal-congenital hyperinsulinism of infancy [Focal-CHI]), the incidence of which in genetically susceptible individuals is not known. METHODS: We genotyped 21,122 Ashkenazi Jewish individuals for two previously identified ABCC8 founder mutations and utilized a clinical database of 61 unrelated Ashkenazi patients with congenital hyperinsulinism of infancy to obtain an estimate of the risk of Focal-CHI in a genetically susceptible fetus. RESULTS: The combined mutation carrier rate in Ashkenazi Jews was 1:52, giving an estimated frequency of homozygosity or compound heterozygosity of 1:10,816 in this population. The risk of Focal-CHI is 1:540 per pregnancy in offspring of carrier fathers. CONCLUSION: We recommend that these mutations be included in the genetic screening program for the Ashkenazi Jewish population. As the risk of Focal-CHI is not expected to be mutation specific, the data reported in this study are useful for counseling all families in which the father was found to carry a recessive ABCC8 or KCNJ11 mutation.
Authors: Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116
Authors: K E Snider; S Becker; L Boyajian; S-L Shyng; C MacMullen; N Hughes; K Ganapathy; T Bhatti; C A Stanley; A Ganguly Journal: J Clin Endocrinol Metab Date: 2012-12-28 Impact factor: 5.958
Authors: N Scott Adzick; Diva D De Leon; Lisa J States; Katherine Lord; Tricia R Bhatti; Susan A Becker; Charles A Stanley Journal: J Pediatr Surg Date: 2018-10-05 Impact factor: 2.545
Authors: G Alkorta-Aranburu; D Carmody; Y W Cheng; V Nelakuditi; L Ma; Jazzmyne T Dickens; S Das; S A W Greeley; D Del Gaudio Journal: Mol Genet Metab Date: 2014-09-28 Impact factor: 4.797
Authors: Leslie J Baier; Yunhua Li Muller; Maria Sara Remedi; Michael Traurig; Paolo Piaggi; Gregory Wiessner; Ke Huang; Alyssa Stacy; Sayuko Kobes; Jonathan Krakoff; Peter H Bennett; Robert G Nelson; William C Knowler; Robert L Hanson; Colin G Nichols; Clifton Bogardus Journal: Diabetes Date: 2015-08-05 Impact factor: 9.461
Authors: Elizabeth Rosenfeld; Lauren Mitteer; Kara Boodhansingh; Susan A Becker; Heather McKnight; Linda Boyajian; Amanda M Ackermann; Jennifer M Kalish; Tricia R Bhatti; Lisa J States; N Scott Adzick; Katherine Lord; Diva D De León Journal: Front Pediatr Date: 2021-07-16 Impact factor: 3.418